ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1329

Subclinical Atherosclerosis Risk in Psoriatic Arthritis: Could It Be Prevented?
Abstract Number: 1330

Subclinical atherosclertoic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study with 806 patients.
Abstract Number: 1331

Carotid Ultrasound Findings in Psoriatic Arthritis: A Case-control Study
Abstract Number: 1332

Identifying the as Patient at Risk: Is Aortic Root Diameter Associated with HLA-B27?
Abstract Number: 1333

Ankylosing Spondylitis Patients at Risk of Developing Aortic Valve Regurgitation, Need for Mandatory Echocardiography?
Abstract Number: 1334

Does Interstitial Lung Disease Represent a Real Comorbidity in Spondyloarthritis Patients? Results from an Ultrasound, Monocentric, Pilot Study
Abstract Number: 1335

Smoking, but Not Use of Complementary and Alternative Medicine Predicts Residual Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Abstract Number: 1336

Bone Mineral Density, Trabecular Bone Score and Proximal Femur 3D-DXA Analysis in Psoriatic Diseases
Abstract Number: 1337

Relationship of the Pro12Ala Polymorphism of the PPARg Gene with Inflammatory Activity, Osteoporosis and Obesity in Patients with Psoriatic Arthritis
Abstract Number: 1338

Identification of Muscle Associated Key Genes to Support Axial Spondyloarthritis Diagnosis by Transcriptomic Approach, the MyoSpA Study
Abstract Number: 1339

COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Abstract Number: 1340

Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study
Abstract Number: 1341

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
Abstract Number: 1342

Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK
Abstract Number: 1343

Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].